Dongsung Pharmaceutical's Breakthrough in Photodynamic Therapy

Dongsung Pharmaceutical's self-developed photosensitizer 'Ponogen (DSP 1944)' was introduced at the Korean Society of Photodynamics conference. With this achievement as an opportunity, Dongsung Pharmaceutical intends to spur clinical preparations to expand the field of photodynamic therapy to peritoneal cancer.

With the development of medical technology, research on developing new cancer treatment methods is being actively carried out. Meanwhile, Dongsung Pharmaceutical's self-developed photosensitizer 'Ponogen (DSP 1944)' which was introduced at the 20th regular academic conference of the Korean Society of Photodynamics held on the 12th, attracted the attention of academia. The Korean Society of Photodynamics holds an annual academic conference to share pioneering research results with photodynamic therapy and diagnosis experts.

At this year's regular symposium, three sessions were held: "The latest treatment and technology development using PDT," "Metabolic disease and immunotherapy technology development," and "Early diagnosis and treatment technology development." At this conference, Professor Hyung-Il Kim of Severance Hospital, Sinchon, demonstrated the effect of intraperitoneal PDT treatment in a mouse model with peritoneal cancer. This is the first case of Dongsung Pharmaceutical's Ponogen applied as non-clinical data before its use in patients with peritoneal cancer. Professor Hyung-Il Kim presented hopeful findings for metastatic peritoneal cancer in this study result.

Furthermore, this research result was also designated as an Oral Presentation at the world-famous PDT international conference 'PDT 2022' to be held in Nancy, France, on October 24. Dongsung Pharmaceutical declared, "This will be an opportunity to showcase the photosensitizer developed by Dongsung Pharmaceutical for the first time on the world stage."

Meanwhile, Dongsung Pharmaceutical received a special award in recognition of its contribution to developing domestic PDT at this academic conference. Dongsung Pharmaceutical plans to conduct a clinical trial using 'Percutaneous Interstitial PDT (PI PDT),' which accesses and treats pancreatic cancer lesions only with local anesthesia without general anesthesia. In addition, Dongsung also intends to use "ultrasound-guided photodynamic therapy (EUS PDT) concurrently."

An official from Dongsung Pharmaceutical stated, "We plan to extend the treatment area to peritoneal cancer while conducting the photodynamic treatment clinical trial for pancreatic cancer with various treatment methods. He counted, "We are designing a clinical trial to lead the field of peritoneal cancer, which has been known as the area of ​​abandonment, to the treatment area."

Ponogen, Photodynamic Therapy, Peritoneal Cancer, Dongsung Pharmaceutical, Clinical Trial